A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders.

A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders. Abstract Text:

J Mendlewicz,E de Bleeker,P Cosyns,G Deleu,F Lotstra,A Masson,C Mertens,M Parent,J Peuskens,E Suy,

The antipsychotic effect of remoxipride was compared to that of haloperidol in a randomized double-blind study with parallel group design comprising 98 patients with schizophrenia or schizophreniform disorder according to DSM-III. After a 3-7 day placebo washout period, patients received either 150-600 mg of remoxipride or 5-20 mg of haloperidol daily for 6 weeks. No significant differences in efficacy were found between the two treatments. Treatment-emergent checklist symptoms such as hypokinesia, rigidity, and tremor occurred more frequently and were more severe during haloperidol than during remoxipride treatment despite a significantly higher concurrent use of anticholinergic drugs in the haloperidol group. Haloperidol-treated patients reported greater increases in sleep and salivation than remoxipride-treated patients. Shoulder shaking and tremor were reported as occurring more frequently in the haloperidol group according to the Simpson and Angus rating scale for extrapyramidal symptoms. In summary, the two drugs seemed to be equally efficacious, though the tolerability profile favoured remoxipride.

A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders. Publishing Authors By Initials

J Mendlewicz,E de Bleeker,P Cosyns,G Deleu,F Lotstra,A Masson,C Mertens,M Parent,J Peuskens,E Suy,

For similar behavioral disciplines and activities: schizophrenic psychology research abstracts see: behavioral disciplines and activities: schizophrenic psychology research

PUBMED ID PMID:

MEDLINE DATE:

A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders. Journal Published:

PUBLICATION TYPE: Randomized Controlled Trial

Journal: Acta psychiatrica Scandinavica. Supplementum

VOLUME: 358

Page Numbers: 138-41

Journal Abbreviation:

ISSN: 0065-1591

DAY: 15

MONTH: 02

YEAR: 1990

A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 370365

A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders. Keywords Mesh Terms:

KEYWORDS: Schizophrenic Psychology

MESH TERMS: drug therapy

Chemical & Substance for Abstract: A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders. Information

Substance Name: Remoxipride

Registry Number: 80125-14-0

Grant and Affiliation Information for A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders.

AFFILIATION: Hospital Erasme, University Clinics of Brussels, Belgium.

Country: DENMARK

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Acta Psychiatr Scand Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders Related Publications

• A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders.
• Brachial artery rupture due to an exostosis: brief report.
• Relationship between the dexamethasone suppression test and the L-tryptophan/competing amino acids ratio in depression.